EN DE

HealthyWay Inc (2587) Fair Value & Analysis

Healthcare · HK · Market cap HK$2.1B

HI HealthyWay Inc 2587 · HK
PriceHK$2.03
Fair ValueHK$1.63
Upside-19.7%
Quality65/100
Watch HealthyWay Inc for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Thin margins · 3.6% net margin
Low debt · generates free cash flow
Ranks above peers (9/13)
Narrow moat 43/100
Evidence: High Range HK$1.22 – HK$2.04 Share as image

Fair value as of: Aug 13, 2026

From 24 valuation models · updated 3 days ago

Fair value updated Aug 13, 2026, revised from HK$1.48 to HK$1.63 (+10.1%) since Aug 6, 2026. Share price −8.1% over the past month.

A solid business, but screening 20% overvalued on our models.

Fair value for all 35,000+ stocks, review alerts and the diversification check: 14 days of Pro free, no card.

What matters now

  • Solid but not exceptional quality (65/100) and above fair value, neither a clear bargain nor a standout compounder.
  • Our model range runs from HK$1.22 (bear) to HK$2.04 (bull), base HK$1.63. The closer the price sits to the lower half, the larger the margin of safety.
  • Quality 65/100 (solid quality) with high evidence: the data supports the verdict.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (19 months)

HK$60.00 HK$2.03 Fair Value HK$1.63 Dec 2024 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

19‑month range HK$2.03 – HK$60.00 · fair‑value band HK$1.22 – HK$2.04 · the HK$2.03 price screens above the HK$1.63 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

HealthyWay Inc (2587) currently trades at HK$2.03, while our model-based Fair Value estimate is HK$1.63, implying the stock looks roughly 19.7% overvalued today. The Quality Score stands at 65/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, HealthyWay Inc generated revenue of HK$1.6B at a net margin of 3.6%. Revenue grew 77.3% year over year. It earns a return on equity of 21.1%. The stock trades on a trailing P/E of 34.0 (as of Jul 2, 2026). Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$1.22 (bear case) to HK$2.04 (bull case); at HK$2.03, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -64% fair-value upside, at -20%, 2587 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF HK$1.00 HK$1.62 HK$2.62 80
Rev-Margin DCF HK$1.11 HK$1.77 HK$3.16 74
ROIC Compounder HK$0.8300 HK$0.9200 HK$1.01 72
All 24 models by family
DCF Models
FCF DCF HK$1.04 HK$1.44 HK$2.67 38
Owner Earnings HK$1.72 HK$3.42 HK$6.88 31
5Y Revenue Exit HK$1.03 HK$1.59 HK$2.76 39
5Y EBITDA Exit HK$1.62 HK$2.78 HK$5.06 41
5Y P/E Exit HK$1.30 HK$2.59 HK$4.37 38
10Y Revenue Exit HK$1.02 HK$1.93 HK$2.53 36
10Y EBITDA Exit HK$1.46 HK$3.17 HK$6.23 37
10Y P/E Exit HK$1.23 HK$2.49 HK$4.58 35
Earnings-Based
Graham-Dodd HK$0.4300 HK$3.02 HK$4.24 54
Lynch FV HK$1.49 HK$2.13 HK$2.77 50
PEG = 1.0 HK$1.49 HK$2.13 HK$2.77 46
EPV HK$0.8200 HK$0.9000 HK$0.9700 59
Multiples
P/E Multiple HK$1.05 HK$1.40 HK$1.75 63
P/S Multiple HK$0.8100 HK$1.08 HK$1.35 58
P/B Multiple HK$0.8100 HK$1.08 HK$1.35 55
EV/EBIT HK$1.22 HK$1.52 HK$1.82 53
EV/EBITDA HK$1.80 HK$2.29 HK$2.79 54
EV/Revenue HK$0.9600 HK$1.23 HK$1.51 43
Asset-Based
NCAV (Graham) HK$0.1600 HK$0.2100 HK$0.3200 50
Growth DCF
Growth DCF HK$1.00 HK$1.62 HK$2.62 80
Rev-Margin DCF HK$1.11 HK$1.77 HK$3.16 74
Economic Profit
Residual Income HK$0.4100 HK$0.5400 HK$2.23 61
ROIC Compounder HK$0.8300 HK$0.9200 HK$1.01 72
Growth Earnings
Growth-Adj P/E HK$1.99 HK$2.85 HK$3.70 68

Widest divergence: Growth Earnings (HK$2.85) versus Asset-Based (HK$0.2100). Highest evidence: Growth DCF (80).

Notify me when 2587 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) HK$1.6B
Revenue growth (YoY) +77.3%
Net margin 3.6%
Return on equity 21.1%
Free cash flow HK$40.2M FY2025
P/E ratio 34.0 as of Jul 2, 2026
More key figures
Operating margin 4.5%
EPS (TTM) HK$0.0100

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 65/100

Of which business quality 65 · Market factors (momentum, volatility) 0

Profitability 70
Margins and returns on capital today
Quality Growth 88
Are margins and returns improving?
Cashflow 35
Earnings quality: real cash, not paper profit
Fin. Strength 70
Balance sheet, leverage, solvency risk
Investment 49
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 83
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

HealthyWay Inc., an investment holding company, provides corporate and digital marketing, and health and medical services in the People's Republic of China.

Full company description

HealthyWay Inc., an investment holding company, provides corporate and digital marketing, and health and medical services in the People's Republic of China. The company offers medical support services for individuals to manage their everyday health and wellness through health membership schemes and other medical support services, including medical consultation services, and supporting services to hospitals. It also involved in the provision of healthcare service packages; and pharmaceutical sales business. In addition, the company offers content services, including wellness content, precision content, and RWS support services; information technology services to corporate and institutional customers; and digital marketing services to advertisers through publishing and posting original marketing articles and brand-building advertisements through platform and other third-party online media channels. Further, the company operates Yihu.com, a health and medical platform. HealthyWay Inc. was founded in 2001 and is headquartered in Fuzhou, the People's Republic of China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

HealthyWay Inc reported revenue of HK$1.6B in FY2025 versus HK$431M in FY2021, a compound +38.0%/yr. Reported net income was HK$55.7M in FY2025.

Growth Quality 90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
HK$1.6B
Latest YoY
+30.1%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+40.0%
Revenue +38.0%/yr
FY21 HK$431M
FY22 HK$569M
FY23 HK$1.2B
FY24 HK$1.2B
FY25 HK$1.6B
Net income
FY21 −HK$157M
FY22 −HK$258M
FY23 −HK$310M
FY24 −HK$268M
FY25 HK$55.7M

2587 screens 20% overvalued. Compare with Veeva Systems Inc →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "HealthyWay Inc Fair Value". https://www.fairvalue-calculator.com/stock/2587

Peer Group

Health Information Services · 125 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 65 · Top 25%
Fair Value upside −20% · Above median
Return on equity (TTM) 21% · Top 25%
Return on assets 6% · Top 25%
Net margin (TTM) 4% · Above median
Operating margin (TTM) 4% · Below median
Revenue growth 77% · Top 25%

Valuation Multiples vs Health Information Services median · lower = cheaper

P/E (TTM) 34.0× · Pricier than median
P/B 7.52× · Pricier than 75% of peers
P/S (TTM) 1.33× · Cheaper than median
P/FCF 6.6× · Cheaper than median
EV/EBITDA 18.0× · Pricier than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 7 · sector 0
FUTURE 100 · sector 29
PAST 84 · sector 7
HEALTH 100 · sector 98
DIVIDEND 0 · sector 42

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
Veeva Systems Inc VEEV $241.51 $91.49 -62%
Pro Medicus Limited PME A$183.71 A$23.74 -87%
BrightSpring Health Services, Inc BTSG $59.68 $21.31 -64%
HealthEquity, Inc HQY $105.50 $56.63 -46%
Hinge Health, Inc HNGE $86.32 $24.03 -72%
10x Genomics, Inc TXG $58.48 $17.18 -71%
Waystar Holding WAY $24.54 $12.86 -48%
XtalPi Holdings 2228 HK$8.19 HK$1.04 -87%
Doximity, Inc DOCS $24.99 $25.91 +4%
Privia Health Group PRVA $21.54 $5.26 -76%

Compare HealthyWay Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is HealthyWay Inc (2587) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of HK$1.63 versus a price of HK$2.03, about −20% (overvalued).
What is the fair value of 2587?
Our model-based fair value for HealthyWay Inc is HK$1.63 (as of Aug 13, 2026), built from audited fundamentals. The current price is HK$2.03.
What is the quality score of 2587?
HealthyWay Inc has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of HealthyWay Inc (2587)?
HealthyWay Inc reported trailing-twelve-month revenue of about HK$1.6B (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 2587?
The net profit margin of HealthyWay Inc is about 3.6%, meaning it keeps roughly 3.6% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track HealthyWay Inc and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.